Phase 2 Breast Cancer Trial, Recruiting NCT06059469 Sponsor: Jules Bordet Institute Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06059469
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give written consent before any study procedures begin, following the guidelines of the institution running the trial
  • Women aged 18 or older
  • People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard cancer performance scale (scores 0 to 2, where 0 means fully active and 2 means up and about more than half of the day)
  • People who have a confirmed diagnosis of triple-negative breast cancer (TNBC) that has spread to other parts of the body and is getting worse, with measurable disease visible on specific scans — either a PET/CT scan done within 2 weeks before the PSMA scan, or a brain MRI done within 4 weeks before the PSMA scan if the cancer has spread to the brain
  • People who have had a specialised PSMA PET/CT scan completed before starting their next round of cancer treatment

Who may not be able to join:

  • People who are pregnant or breastfeeding
  • People who have another active cancer diagnosis at the same time
  • People who have received another experimental treatment or investigational drug within the past 30 days
  • People whose cancer has spread only to the skin
  • People with a serious medical, mental health, or surgical condition that, in the opinion of the treating doctor, could interfere with completing the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 025413095

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jules Bordet Institute
Registry
ClinicalTrials.gov
Start date
30 May 2022
Est. completion
2 June 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Assess PSMA expression in progressive metastatic TNBC patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov